article thumbnail

470% price increases

World of DTC Marketing

Humira’s net price—which subtracts discounts and rebates—increased by 110% between 2009 and 2018, from $16,663 per year to $35,041 per year. AbbVie has obtained or applied for over 250 patents on Humira to block competition from lower-priced biosimilars. The last of these patents is set to expire in 2037. The post 470% price increases.

article thumbnail

Biogen’s $900 million settlement signals scrutiny on speaker fees

Pharmaceutical Technology

In 2009, former Biogen employee Michael Bawduniak filed a lawsuit claiming that Biogen had violated the False Claims Act and the Anti-Kickback Statute by providing millions of dollars to healthcare providers (HCPs) as an incentive to prescribe three of its multiple sclerosis (MS) drugs. BIIB107 is a monoclonal antibody that targets ?4

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Call to arms as UK falls back in medicines manufacturing

pharmaphorum

Over the last 25 years, the headcount in the medicines manufacturing sector has fallen by 7,000 and since 2009 production volumes have fallen by nearly a third (29%), suggesting “faltering attractiveness” of the UK for manufacturing.

article thumbnail

Astellas loses bid to block Lexiscan generics in US

pharmaphorum

In an update on the litigation posted this morning, Astellas confirmed that the Court of Appeals for the Federal Circuit (CAFC) had upheld a lower court ruling that Hospira’s generic does not infringe any of the patents that are protecting Lexiscan (regadenoson injection) from competition.

article thumbnail

Being bold with your IP legal investment strategy during challenging times

Clarivate

Budgets and staffing are tight, competitive pressures are on the rise, and clients and business leaders are demanding more for less — without compromising quality. The importance of IP is elevated during a downturn as companies seek to bolster their revenue and gain competitive advantage.

article thumbnail

Indivior must go to court over addiction drug monopoly claim

pharmaphorum

Indivior has failed in its bid to prevent a lawsuit claiming that it illegally blocked competition to opioid addiction drug Suboxone from coming to court in the US. Indivior made an application for a judgment in its favour without coming to trial, but that has been denied by Judge Mitchell Goldberg in a Philadelphia court.

article thumbnail

Gaining Power Through Evidence-Based Selling

MedReps

There are plenty of successful sales reps who swear by it, so learning how to utilize this method can give you the upper hand against the competition. How can you get started using this method? Ready to get started? Keep reading as we go over just how well this approach will work to help you meet your sales goals.